Evidence map›Paper›PMID 31201644›Full record

Trial reportInternational journal of hematology2019

Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.

Takayuki Takachi, Yuki Arakawa, Hiroyoshi Nakamura, Tomoyuki Watanabe, Yuki Aoki, Junjiro Ohshima, Yoshihiro Takahashi, Masahiro Hirayama, Takako Miyamura, Kanji Sugita and 5 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Takayuki TakachiDepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
Yuki ArakawaDepartment of Hematology and Oncology, Saitama Children's Medical Center, Saitama, Japan.
Hiroyoshi NakamuraDepartment of Pharmacy, Chiba University Hospital, Chiba, Japan.
Tomoyuki WatanabeDepartment of Nutrition and Health, Faculty of Psychological and Physical Science, Aichi Gakuin University, Nisshin, Japan.
Yuki AokiDepartment of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
Junjiro OhshimaDepartment of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan.
Yoshihiro TakahashiDepartment of Pediatrics, Aomori Prefectural Central Hospital, Aomori, Japan.
Masahiro HirayamaDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Takako MiyamuraDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
Kanji SugitaDepartment of Pediatrics, Faculty of Medicine, University of Yamanashi, Chuo, Japan.
Katsuyoshi KohDepartment of Hematology and Oncology, Saitama Children's Medical Center, Saitama, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Eiichi IshiiDepartment of Pediatrics, Ehime University Graduate School of Medicine, Toon, Japan.
Shuki MizutaniDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. tomizawa-d@ncchd.go.jp.ORCID http://orcid.org/0000-0003-1520-7007
National Hospital Organization · JPSaitama Children's Medical Center · JPAichi Gakuin University · JPAomori Prefectural Central Hospital · JPChiba University Hospital · JPEhime University · JPMie University · JPNational Center For Child Health and Development · JPSapporo Hokuyu Hospital · JPThe University of Osaka · JPTokyo Medical and Dental University · JPUniversity of Yamanashi · JP

Funding

Japan Agency for Medical Research and Development 17ck0106382s0101Japan Agency for Medical Research and Development 18ck0106436h0001Ministry of Health, Labour and Welfare H23-GanRinsho-Ippan-014Ministry of Health, Labour and Welfare H26-GanRinsho-Shitei-068National Center for Child Health and Development 30-1
6 · The paper itself

Abstract

Individual busulfan (BU) dosing based on pharmacokinetic (PK) data is preferable for hematopoietic stem cell transplantation (HSCT) conditioning, but information on BU PK in infants is scarce. We report BU PK data on HSCT conditioning for infants with KMT2A-gene-rearrangement-positive acute lymphoblastic leukemia (MLL-r ALL). Infants showed wide variation in BU PK indices, such as clearance (CL) and volume of distribution (V

Indexed as

BusulfanHematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningAllograftsDisease-Free SurvivalFemaleHumansInfantMaleSurvival RateBusulfanBusulfanHematopoietic stem cell transplantationInfantKMT2APharmacokinetics

Identifiers

PMID31201644
OpenAlexW2950430416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.